medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction

Korean Journal of Internal Medicine 2019년 34권 5호 p.1030 ~ 1039
 ( Choi Ki-Hong ) - Sungkyunkwan University School of Medicine Department of Medicine

 ( Lee Ga-Yeon ) - Sungkyunkwan University School of Medicine Department of Medicine
 ( Choi Jin-Oh ) - Sungkyunkwan University School of Medicine Department of Medicine
 ( Jeon Eun-Seok ) - Sungkyunkwan University School of Medicine Department of Medicine
 ( Lee Hae-Young ) - Seoul National University Hospital Department of Internal Medicine
 ( Lee Sang-Eun ) - University of Ulsan College of Medicine Department of Internal Medicine
 ( Kim Jae-Joong ) - University of Ulsan College of Medicine Department of Internal Medicine
 ( Chae Shung-Chull ) - Kyungpook National University School of Medicine Department of Internal Medicine
 ( Baek Sang-Hong ) - Catholic University College of Medicine Department of Internal Medicine
 ( Kang Seok-Min ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Choi Dong-Ju ) - Seoul National University Bundang Hospital Department of Internal Medicine
 ( Yoo Byung-Su ) - Yonsei University Wonju College of Medicine Department of Internal Medicine
 ( Kim Kye-Hun ) - Chonnam National University Hospital Heart Research Center
 ( Cho Myeong-Chan ) - Chungbuk National University College of Medicine Department of Internal Medicine
 ( Park Hyun-Young ) - National Institute of Health
 ( Oh Byung-Hee ) - Seoul National University Hospital Department of Internal Medicine

Abstract


Background/Aims: It is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF.

Methods: The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed.

Results: Among patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47).

Conclusions: In the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.

키워드

Beta-blocker; Heart failure with reduced ejection fraction; Carvedilol; Bisoprolol
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS